Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:10:24.974Z.
Calculation as of: 2026-10-06T19:10:24.974Z.
Quote observation: 2026-10-06T19:09:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 017b786e338061c10a4665063360519c0b30ae95494f37f63af909a19a8b52dc
PE RATIO
N/A
PE RATIO AVG TTM
N/A
PE RATIO AVG 3Y
N/A
PE RATIO AVG 5Y
N/A
PE RATIO AVG 10Y
N/A
PE RATIO AVG 15Y
N/A
PE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$58.61M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adicet Bio, Inc. (ACET) | $59.64M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.49M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.22M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.62M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $60.40M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $58.61M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $58.21M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $60.95M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.38M | N/A | N/A | N/A | N/A |
| Talphera, Inc. (TLPH)vs › | $57.09M | N/A | 0.43 | 0.43 | 0.43 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$6.38
Forward EPS (Est.)
$-6.36
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2018-03-29 | 64.57 |
| 2018-03-28 | 71.17 |
| 2018-03-27 | 75.76 |
| 2018-03-26 | 73.80 |
| 2018-03-23 | 79.40 |
| 2018-03-22 | 88.83 |
| 2018-03-21 | 99.08 |
| 2018-03-20 | 100.29 |
| 2018-03-19 | 101.57 |
| 2018-03-16 | 100.76 |
| 2018-03-15 | 100.56 |
| 2018-03-14 | 101.64 |
| 2018-03-13 | 104.13 |
| 2018-03-12 | 107.16 |
| 2018-03-09 | 107.16 |
| 2018-03-08 | 109.05 |
| 2018-03-07 | 114.64 |
| 2018-03-06 | 115.93 |
| 2018-03-05 | 118.82 |
| 2018-03-02 | 119.50 |
| 2018-03-01 | 123.81 |
| 2018-02-28 | 131.43 |
| 2018-02-27 | 133.11 |
| 2018-02-26 | 138.84 |
| 2018-02-23 | 140.53 |
| 2018-02-22 | 132.44 |
| 2018-02-21 | 132.71 |
| 2018-02-20 | 131.43 |
| 2018-02-16 | 126.44 |
| 2018-02-15 | 122.80 |
| 2018-02-14 | 121.92 |
| 2018-02-13 | 123.00 |
| 2018-02-12 | 121.99 |
| 2018-02-09 | 114.58 |
| 2018-02-08 | 111.21 |
| 2018-02-07 | 109.32 |
| 2018-02-06 | 108.38 |
| 2018-02-05 | 114.17 |
| 2018-02-02 | 114.85 |
| 2018-02-01 | 112.89 |
| 2018-01-31 | 109.32 |
| 2018-01-30 | 106.09 |
| 2018-01-29 | 109.39 |
| 2018-01-26 | 113.77 |
